Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008283/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is an open-label, single-arm, multicenter, Phase IIIb study to evaluate the safety and
tolerability of Herceptin SC in combination with Perjeta IV plus docetaxel in female patients
with HER2-positive metastatic or locally recurrent breast cancer. Enrolled patients are to
receive study medication until disease progression, unacceptable toxicity, withdrawal of
consent, death, or predefined study end, whichever occurs first. The anticipated time on
study treatment is approximately 24 months. The target sample size is 400.
提供机构：
Vivli
创建时间：
2022-07-19
